206 related articles for article (PubMed ID: 19570220)
1. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
Hesson LB; Dunwell TL; Cooper WN; Catchpoole D; Brini AT; Chiaramonte R; Griffiths M; Chalmers AD; Maher ER; Latif F
Mol Cancer; 2009 Jul; 8():42. PubMed ID: 19570220
[TBL] [Abstract][Full Text] [Related]
2. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.
Djos A; Martinsson T; Kogner P; Carén H
Mol Cancer; 2012 Jun; 11():40. PubMed ID: 22695170
[TBL] [Abstract][Full Text] [Related]
3. DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghavamzadeh A; Ghaffari SH
Leuk Res; 2017 Oct; 61():33-38. PubMed ID: 28869817
[TBL] [Abstract][Full Text] [Related]
4. Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia.
Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghaffari SH
Ann Hematol; 2019 Dec; 98(12):2719-2727. PubMed ID: 31486880
[TBL] [Abstract][Full Text] [Related]
5. Frequent epigenetic inactivation of RASSF10 in thyroid cancer.
Schagdarsurengin U; Richter AM; Wöhler C; Dammann RH
Epigenetics; 2009 Nov; 4(8):571-6. PubMed ID: 19934646
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma.
Guo W; Dong Z; Guo Y; Shen S; Guo X; Kuang G; Yang Z
Mol Carcinog; 2016 Nov; 55(11):1655-1666. PubMed ID: 26456015
[TBL] [Abstract][Full Text] [Related]
7. KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia.
Shinawi T; Hill V; Dagklis A; Baliakas P; Stamatopoulos K; Agathanggelou A; Stankovic T; Maher ER; Ghia P; Latif F
Epigenetics; 2012 Mar; 7(3):211-5. PubMed ID: 22430796
[TBL] [Abstract][Full Text] [Related]
8. N-terminal RASSF family: RASSF7-RASSF10.
Underhill-Day N; Hill V; Latif F
Epigenetics; 2011 Mar; 6(3):284-92. PubMed ID: 21116130
[TBL] [Abstract][Full Text] [Related]
9. RASSF6 is a novel member of the RASSF family of tumor suppressors.
Allen NP; Donninger H; Vos MD; Eckfeld K; Hesson L; Gordon L; Birrer MJ; Latif F; Clark GJ
Oncogene; 2007 Sep; 26(42):6203-11. PubMed ID: 17404571
[TBL] [Abstract][Full Text] [Related]
10. The RASSF proteins in cancer; from epigenetic silencing to functional characterization.
Richter AM; Pfeifer GP; Dammann RH
Biochim Biophys Acta; 2009 Dec; 1796(2):114-28. PubMed ID: 19344752
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis.
Hill VK; Underhill-Day N; Krex D; Robel K; Sangan CB; Summersgill HR; Morris M; Gentle D; Chalmers AD; Maher ER; Latif F
Oncogene; 2011 Feb; 30(8):978-89. PubMed ID: 20956940
[TBL] [Abstract][Full Text] [Related]
12. RASSF6; the Putative Tumor Suppressor of the RASSF Family.
Iwasa H; Jiang X; Hata Y
Cancers (Basel); 2015 Dec; 7(4):2415-26. PubMed ID: 26690221
[TBL] [Abstract][Full Text] [Related]
13. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
[TBL] [Abstract][Full Text] [Related]
14. RASSF10 is epigenetically inactivated and induces apoptosis in lung cancer cell lines.
Wang Y; Ma T; Bi J; Song B; Zhou Y; Zhang C; Gao M
Biomed Pharmacother; 2014 Apr; 68(3):321-6. PubMed ID: 24433832
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation status of Ras-association domain family members in pheochromocytoma.
Richter AM; Zimmermann T; Haag T; Walesch SK; Dammann RH
Front Endocrinol (Lausanne); 2015; 6():21. PubMed ID: 25750636
[TBL] [Abstract][Full Text] [Related]
16. RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer.
Wei Z; Chen X; Chen J; Wang W; Xu X; Cai Q
Biochem Biophys Res Commun; 2013 Mar; 432(4):632-7. PubMed ID: 23428420
[TBL] [Abstract][Full Text] [Related]
17. RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.
Mezzanotte JJ; Hill V; Schmidt ML; Shinawi T; Tommasi S; Krex D; Schackert G; Pfeifer GP; Latif F; Clark GJ
Epigenetics; 2014 Nov; 9(11):1496-503. PubMed ID: 25482183
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Promoter Methylation of the Tumour Suppressor RASSF10 and Its Growth Inhibitory Function in Breast Cancer.
Richter AM; Walesch SK; Dammann RH
Cancers (Basel); 2016 Feb; 8(3):. PubMed ID: 26927176
[TBL] [Abstract][Full Text] [Related]
19. RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice.
Richter AM; Woods ML; Küster MM; Walesch SK; Braun T; Boettger T; Dammann RH
Oncogene; 2020 Apr; 39(15):3114-3127. PubMed ID: 32047266
[TBL] [Abstract][Full Text] [Related]
20. RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer.
Li Z; Chang X; Dai D; Deng P; Sun Q
Oncol Rep; 2014 Apr; 31(4):1661-8. PubMed ID: 24573726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
